SCHEMBL18471685

SCHEMBL18471685

CC(C)(C)N1CC(NCc2ccccc2)C1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACHE P22303 10/20 0.51
BACE1 P56817 10/20 0.51
BCHE P06276 9/20 0.51
GRIN2B Q13224 2/20 0.50
CARM1 Q86X55 2/20 0.48
PRMT6 Q96LA8 2/20 0.48
FYN P06241 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
RAB9A P51151 1/20 0.46
OPRM1 P35372 2/20 0.45
OPRL1 P41146 2/20 0.45
FABP6 P51161 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18484552 0.86 ACHE (0.49) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL955623 0.85 ACHE (0.62) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL21618396 0.84 ACHE (0.50) ACHEBACE1BCHEMEN1KMT2A
SCHEMBL9965855 0.81 ACHE (0.54) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL14805850 0.81 ALDH1A1 (0.60)
SCHEMBL19100319 0.81 FUCA1 (0.48) ACHEBACE1BCHE
SCHEMBL28701109 0.80 KDM1A (0.42) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL24928272 0.78 ACHE (0.54) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL17320169 0.78 ACHE (0.58) ACHEBACE1BCHEGRIN2BCARM1
SCHEMBL25093393 0.77 ACHE (0.50) ACHEBACE1BCHEGRIN2BCARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 US disclosed
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KUMQUAT BIOSCIENCES INC. (US) 2023-05-16 US disclosed
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-03-02 US disclosed
US-20170037059-A1 GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2017-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648254-B2 Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling KRAS, NRAS, BRAF ACHE 4819/4885BACE1 2462/4885BCHE 4667/4885
US-20230064360-A1 HETEROCYCLES AND USES THEREOF KRAS, HRAS, TP53 ACHE 4839/4885BACE1 3901/4885BCHE 4311/4885
US-20170037059-A1 GYRASE INHIBITORS TOP1, CA7, TOP2B ACHE 2058/4885BACE1 3790/4885BCHE 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.